Safety and Immune Response to a Multi-component Immune Based Therapy (MKC1106-PP) for Patients With Advanced Cancer.
Condition Ovarian|Melanoma|Renal|Prostate|Colorectal|Endometrial Carcinoma|Cervical Carcinoma|Testicular Cancer|Thyroid Cancer|Small Cell Lung Carcinoma|Mesothelioma|Breast Carcinoma|Esophageal Carcinoma|Gastric Cancer|Pancreatic Carcinoma|Neuroendocrine Cancer|Liver Cancer|Gallbladder Cancer|Biliary Tract Cancer|Anal Carcinoma|Bone Sarcomas|Soft Tissue Sarcomas|Carcinoma of Unknown Origin, Primary Estimated Enrollment: 12 Age Group: 18 Years and older (Adult, Senior) Gender: All Study Type: Interventional Study Design Allocation: Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment Study ID Numbers: MKC1106-PP-001 Study First Received: January 12, 2007 Last Updated: August 2, 2010 Estimated Primary Completion Date: September 2009 Primary Outcome Measures: To determine the immunologic response to the treatment with MKC1106-PP regimen and 2) to determine the safety and adverse event profile of MKC1106-PP|to determine the blood plasmid levels by PCR analysis|measure cytokine...
Continue reading